Cedré B, Hernández Y, Delgado I, Izquierdo L, García L

Language: Spanish
References: 12
Page: 31-34
PDF size: 153.61 Kb.

ABSTRACT

Serum bactericidal assay is considered the most efficient tool for measuring the immunity status in people vaccinated against N. meningitidis and it is the analytical support for the development of polysaccharide vaccines. Good Manufacturing Practice and Quality Control of Pharmaceutical Products regulate the validation procedure for manufacturing process and the analysis and control methods, especially for bioassays that are more variable than physicochemical assays. For that reason, the validation of bactericidal assay for the tilt method was carried out by the determination of precision, specificity, accuracy and robustness. The results were in the range of acceptance criteria, that is why this assay is considered suitable for the evaluation of the immune response induced by A, C and W135 polysaccharide vaccines against meningococcal meningitis.

REFERENCES

1. Goldschneider I, Gotschlich E, Artenstein M. Human immunity to the meningococcus. I. The role of humoral antibodies. JExp Med 1969;129:1307–26.

2. Sadarangani M, Pollard A. Serogroup B meningococcal vaccines an unfinished story. Lancet Infect Dis 2010;10:112–4.

3. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005;23:2222–7.

4. Zollinger W, Moran E, Schmiel D. Characterization of an Antibody Depletion Assay for Analysis of Bactericidal Antibody Specificity. Clin and Vaccine Immunol 2009;16:1789-95.

5. Wedege E, Kuipers B, Bolstad K, van Dijken H, Oddvar L, Vermont C, et al. Antibody Specificities and Effect of Meningococcal Carriage in Icelandic Teenagers Receiving the Norwegian Serogroup B Outer Membrane Vesicle Vaccine. Infect and Immun 2003;71:3775–81.

6. Mountzouros K, Howell A. Detection of Complement-Mediated Antibody-Dependent Bactericidal Activity in a Fluorescence- Based Serum Bactericidal Assay for Group B Neisseria meningitidis. J Clin Microb 2000;38:2878-94.

7. Camaraza M, Ochoa R, Arnet A, Sotolongo F, Martínez I, Cuevas I, et al. Inmunogenicidad inducida por la vacuna antimeningocócica VA-MENGOC-BC® contra la cepa de N. meningitidis ATCC C11 en adolescentes después de 12 años de vacunados. Revista Cubana de Medicina Tropical 2004;56(1)26-30.

8. Borrow R, Aaberge I, Santos G, Eudey T, Oster P, Glennie A, et al. Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle Vaccine. Clin and Diag Lab Immun 2005;12:970-6.

9. Centro para el Control Estatal de la Calidad de los Medicamentos. República de Cuba. Ministerio de SaludPública. Regulación No. 41-2007. Validación de métodos analíticos. Ciudad de la Habana: CECMED; 2007.

10. Joseph H, Balmer P, Bybel M, Papa T, Ryall R, Borrow R. Assignment of Neisseria meningitidis Serogroups A, C, W135, and Y Anticapsular Total Immunoglobulin G (IgG), IgG1 and IgG2 Concentrations to Reference Sera. Clin and Diag Lab Immun 2004;11:1-5

11. Hellerud BC, Aase A, Herstad TK, Meyer L, Kristiansen LH, Siebke A, et al. Critical Roles of Complement and Antibodies in Host Defense Mechanisms against Neisseria meningitidis as Revealed by Human Complement Genetic Deficiencies. Infect Immun 2010;2: 802-9.

12. Malanska S, Gheesling L, Libutti D, Donaldson K, Harakeh H, Dykes J. Standardization and multilaboratory comparison of N. meningitidis serogroups A and C serum bactericidal assay. Clin and Diag Lab Immun 1997;4:156-67.